Pinealon
A synthetic tripeptide from Russian bioregulator research; its small regional literature lacks independent replication, and it holds no approval anywhere.
What it is
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the same Russian 'peptide bioregulator' school that produced Epithalon, marketed for brain aging and cognitive protection.
Its literature is small, regional and largely from the originating research lineage — cell and animal studies plus limited Russian clinical reports, without independent replication or any Western regulatory review. It circulates as capsules and vials through supplement-adjacent channels.
What researchers have actually studied it for
Neuronal aging and cognitive protection in the Russian bioregulator literature — small, regional, and without independent replication.
How it works
The bioregulator school proposes that short peptides like Pinealon act epigenetically — entering cells and modulating gene expression relevant to neuronal maintenance. Supporting data comes from the originating laboratories' cell and animal work; independent mechanistic confirmation is absent.
The molecule itself
A tripeptide — Glu-Asp-Arg — from the bioregulator school's short-peptide catalog. The program proposes such fragments enter nuclei and modulate gene expression organ-specifically; for a charged tripeptide, both the cell entry and the specificity are the contested steps.
Where it came from
Part of the St. Petersburg bioregulator program's catalog of organ-targeted short peptides developed from the 1980s onward, Pinealon is positioned as the 'brain peptide' sibling of Epithalon. The program's sweeping longevity claims have never been independently replicated.
The timeline
1980s+
St. Petersburg bioregulator program catalogs organ-targeted short peptides.
2000s
Pinealon positioned as the brain member; regional studies accumulate.
2010s+
Global supplement-channel commerce without independent replication.
What the research record actually contains
- Cell and rodent studies from the originating research lineage.
- Russian-language clinical reports outside modern trial standards.
- No independent replication; no Western trials; no regulatory review anywhere.
What could change this assessment
Same as its lineage: commercially persistent, scientifically frozen pending independent replication no one is positioned to run.
What's known about risks
The originating literature reports benign tolerability; no independent safety characterization exists.
Where it stands legally
No approval anywhere; supplement-adjacent and research-chemical channels only.
Worth asking a licensed provider
- 1.Is there any independently verified evidence here at all?
- 2.For cognitive concerns, what established work-up and interventions come first?
- 3.How would we even measure benefit from an unvalidated compound?
Common claims, corrected
“It's brain-targeted by design.”
Reality: The organ-specificity claim is the program's central unreplicated hypothesis — mainstream biology hasn't confirmed tripeptides sorting themselves by destination organ.
“Different bioregulators are independent products.”
Reality: Epithalon, Pinealon and their siblings are one research lineage's claims across many labels — evaluating one evaluates all.
Pinealon FAQ
What is Pinealon supposed to do?
The bioregulator school markets it for brain aging and cognitive resilience. Its evidence is the originating lineage's cell, animal and small clinical work — never independently replicated.
Is Pinealon related to Epithalon?
Same research school, same short-peptide concept, different target organ — Epithalon is positioned for the pineal gland and aging, Pinealon for the brain.
Is Pinealon approved or regulated anywhere?
No — it has no drug approval in any country and circulates through supplement-adjacent channels without regulatory review.
How is Pinealon different from Epithalon?
Different tripeptide, different marketed organ (brain vs pineal/aging), same school and evidence profile. The catalog's breadth is branding architecture, not differentiated science.
Are there any Western Pinealon trials?
None registered — the file is regional literature plus commerce, checkable in minutes on the registries.